Drug intelligence / Profile preview

GSK2132231A + dacarbazine

Development stage: Discontinued
Lead developer: GSK
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Intravenous

Overview

GSK2132231A + dacarbazine is a discontinued experimental **combination therapy** for cancer, specifically for unresectable/metastatic malignant melanoma. \n**GSK2132231A** (also known as astuprotimut-R, zastumotide, or MAGE-A3 ASCI) is a recombinant **MAGE-A3 antigen-specific cancer immunotherapeutic vaccine**, designed to stimulate an immune response against cells expressing the MAGE-A3 tumor antigen. It is formulated with the AS15 immunological adjuvant system to enhance immunogenicity. **Dacarbazine** is an established alkylating chemotherapy agent that causes DNA damage to cancer cells. \nThis combination was developed to target MAGE-A3-positive tumors (melanoma) and intended to harness both direct cytotoxic (dacarbazine) and tumor-targeted immunotherapeutic effects (GSK2132231A). The regimen was administered via intramuscular (GSK2132231A) and intravenous (dacarbazine) routes. \nThe development was discontinued after clinical trials failed to demonstrate sufficient clinical benefit.

Other names: zastumotiderecMAGE-A3 recombinant protein + immunological Adjuvant System

Targets

MAGEA3 (Melanoma-associated antigen 3)DNA

Beyond the preview

Go deeper on GSK2132231A + dacarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2132231A + dacarbazine.

Explore the full profile